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ABSTRACT 
 
Molecular Studies Involving the Rev Proteins of Caprine Arthritis Encephalitis Virus and Visna 
Virus  
 
by 
 
Bridget M. Graves 
 
Caprine Arthirtis Encephalitis Virus (CAEV) and Visna Virus are two viruses of the lentivirus 
family.  They encode three structural genes (gag, pol, and env) and two regulatory genes (rev and 
tat).  The Rev protein regulates Gag, Pol, and Env expression by transporting their mRNAs to 
the cytoplasm by binding to the RRE (Rev Response Element) found on their mRNAs.  Previous 
studies have indicated that Rev may be toxic to transfected cells, overexpression of exogenous 
RREs or a better binding RRE can inhibit Rev activity and Rev-C (CAEV Rev) can trans-
activate RRE-V (Visna Virus RRE).  To test these possibilities FACS analysis, RNA binding 
assays, cotransfections, and SELEX were done.  The results indicated that Rev is not acutely 
toxic to cells, inhibition of Rev activity could not be achieved by making a better binder or 
through expression of exogenous RREs, and Rev-C can trans-activate RRE-V implicating 
conservation of Rev/RRE interactions in lentiviruses. 
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CHAPTER 1 
INTRODUCTION 
 
Lentiviruses are complex, non-oncogenic retroviruses known for their slow progression 
of disease (Joag et al. 1996, Pollard and Malim 1998).   The most well known lentivirus is the 
Human Immunodeficiency Virus type 1 (HIV-1) that infects humans and causes Acquired 
Immunodeficiency Syndrome (AIDS) by replicating in and destroying both lymphocytes and 
macrophages (Luciw 1996, Clements and Zink 1996).  The resulting immunological disease 
leads to opportunistic infections, neurologic disorders, unusual forms of cancer, and eventually 
death (Luciw 1996).  Caprine Arthritis-Encephalitis Virus (CAEV), which infects goats, and 
Visna Virus, which infects sheep, are also lentiviruses but their course of disease is different 
from that of HIV-1.  CAEV and Visna Virus generally are more organ specific in their pathology 
and replicate predominately in macrophages (Clements and Zink 1996, Joag et al. 1996).  While 
Lentiviruses may differ in their tissue tropism, they do share similar genetic compositions and 
can therefore be studied generally as one virus.  Any drug or vaccine discovered for one virus is 
likely to be applicable to all lentiviruses.   
Lentiviral Disease and Pathology 
 Two characteristics of Lentiviral infections important for their progression of disease is 
persistence in the face of host immune responses and antigenic variation (Blacklaws et al. 1995, 
Clements and Zink 1996, Joag et al. 1996).  Lentiviruses are able to persist in the host by 
integrating into their hosts genome.  In doing so, their host is never able to completely clear the 
virus (Joag et al. 1996).  The antigenic variation characteristic of Lentiviruses is a result of a 
defect in their replicative machinery.  Lentiviruses use reverse transcriptase, an error prone 
enzyme, to replicate.  This results in a high number of mutations and a continuous changing of 
antigenic markers for the infecting virus, thereby allowing the virus to evade the host immune 
response (ibid).  The use of antiviral drugs against lentiviral infections has also led to variation of 
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the viruses as they mutate to drug resistance as a result of drug therapy (Joag et al. 1996, Luciw 
1996).   
 Lentiviral infections typically progress through a specific pattern of phases as shown in 
Figure 1 (Joag et al. 1996).  After initial infection, there is intense productive viral replication in 
lymphocytes and/or macrophages along with immunologic activation of the cells that distribute 
virus throughout the body (ibid).  This is known as the acute phase of infection.  The next phase 
involves the hosts antiviral immune response that leads to a reduction of viral replication, but an 
incomplete clearing of the virus from the system.  This is known as the clinical latency phase.  
During this time, which lasts for months to years, the virus continues to replicate in virally 
disseminated organs and tissues.  The late phase of viral infection involves a resurgence of viral 
replication due to the faltering of the exhausted and/or compromised hosts immune system.  
This leads to symptoms of disease and eventually death of the host. 
 Lentiviruses primarily infect and replicate in macrophages and lymphocytes which are 
terminally differentiated, non-dividing immune cells.  Lentiviruses can be classified into two 
groups based on their cell tropism.  HIV, Feline Immunodeficiency Virus (FIV), and Simian 
Immunodeficiency Virus (SIV) are examples of Lentiviruses that can replicate in both 
lymphocytes and macrophages.  These viruses cause both immunodeficiency disease and organ 
specific inflammatory disease.  In contrast, the Lentiviruses CAEV and Visna Virus replicate 
mainly in macrophages and they cause only organ specific disease.  The cell tropism is the 
primary reason for the differences in disease caused by the two groups (Clements and Zink 1996, 
Joag et al. 1996).  
 Goats infected with CAEV can develop arthritis, encephalitis, and mastitis.  Vertical 
transmission of CAEV via colostrum between dam and kid is the main mode of transmission 
between goats.  However, horizontal transmission (animal to animal) of CAEV is on the rise 
(Clements and Zink 1996).  Sheep infected with Visna Virus can develop chronic pneumonia and 
a neurologic condition characterized by wasting and paralysis.  There currently is no effective 
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treatment or vaccine available to treat lentiviral diseases.  Because the viruses will eventually kill 
the infected animals, infected animals are culled in an effort to control the spread of infection 
among herds.  Understandably, this is a costly method of control and it has a severe impact on 
the agricultural industry yearly.  Therefore, any effective treatment or vaccine that can be 
developed would save millions in lost animals yearly worldwide.   
 
 
 
 
Figure 1.  Typical Course of  a Lentivirus Infection.  Reprinted from Jawetz, Melnick and 
Adelbergs Medical Microbiology, 20th ed., Appleton and Lange Publishers, 1995. 
 
 
Lentiviral Structure and Genomic Organization 
 Lentiviruses are a subfamily of retroviruses that have a complex genome and structure.  
Figure 2 shows a diagram of the HIV-1 structure which can serve as the model for all 
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lentiviruses.  The lipid bilayer membrane contains the envelope glycoproteins gp120 and gp41, 
which bind to the host CD4+ cells.  The gag matrix protein (MA) surrounds the gag capsid 
protein (CA) that encircles the nucleocapsid protein, integrase, reverse transcriptase, protease, 
and other viral enzymes.  The gag nucleocapsid (NC) protein surrounds the two single stranded 
RNA copies of the viral genome.   
 
 
  
Figure 2.  Lentivirus Structure (Reprinted from Fields Virology, Vol. 2, Lippincott-Raven 
Publishers, p. 1886).  This Figure of HIV-1 is representative of the general features of all 
lentiviruses. 
    
 
The amino acid sequences of CAEV and Visna Virus have moderate homology with each 
other as seen in Figure 3.  As one might expect, they have essentially the same genomic 
organization as demonstrated in Figure 4 (Joag et al. 1996, Luciw 1996).  They have three 
structural genes known as gag, pol, and env.  The gag gene encodes the capsid, nucleocapsid, 
and core proteins.  The pol gene encodes the viral enzymes protease, reverse transcriptase, 
RNase H, integrase, and dUTPase.  Protease is responsible for cleaving the core proteins into 
 13 
their final forms.  Reverse transcriptase is responsible for synthesizing the single stranded RNA 
template into DNA.  RnaseH functions by degrading the RNA from the RNA/DNA hybrids 
made during reverse transcription.  Integrase is responsible for integration of the double stranded 
DNA viral genome into the host cell DNA.  The enzyme dUTPase helps to maintain a low ratio 
of dUTP to dTTP in the host cell and thus minimizing the incorporation of uracil into DNA 
(Turelli et al. 1996, Turelli et al. 1997, Pe′tursson et al. 1998).  The env gene encodes the 
envelope glycoproteins gp42 and gp135 that are responsible for binding of the virion to the host 
cell receptors. 
 
VMV KV1772
VMV K 1514V
VMV SA-OMVV
CAEV Co
1% difference  
 
Figure 3.  Phylogenetic Relationship Between Strains of CAEV and Visna Virus.  The genomic 
sequences of the CAEV Cork strain (CAEV Co), Visna Virus strains 1514 (VMV KV1514), 
1772 (VMV KV1772) and SA-OMVV (South African Visna Virus strain) were compared using 
the Neighbor Joining Method of Saitou and Hei using Vector NTI, Suite 6.0 (InforMax Corp.).  
The horizontal distance indicates the degree of relatedness between the sequences. 
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Gag
Pol
Vif
Tat
Env
Rev5 LTR’ 3 LTR’
RRE
 
 
Figure 4.  CAEV and Visna Virus Genomic Organization.  The stacked boxes represent the three 
Open Reading Frames (ORFs).  The structural genes are gag, pol, and env. The three regulatory 
genes are vif, tat, and rev.  Rev is encoded in the env open reading frame and the Rev Response 
Element (RRE) is located in the env ORF.  LTR refers to Long Terminal Repeats.      
 
 
At the ends of the CAEV and Visna Virus genomes are two long terminal repeats (LTRs).  
They are involved in the integration into the host cell genome and also contain signals for 
transcriptional activation, RNA synthesis, capping, and polyadenylation.  There is one accessory 
gene called vif (viral infectivity factor) that facilitates spread of the virus (Clements and Zink 
1996).  There are also two regulatory genes called tat and rev that are absolutely necessary for 
productive viral replication.  Tat is the transcriptional trans-activator of CAEV and Visna Virus.  
Rev is the regulator of viral RNA transport in CAEV and Visna Virus.  There is another 
important element in the CAEV and Visna Virus genome:  the RRE (Rev Response Element).  It 
is a cis functional element that  is necessary for transportation of unspliced and partially spliced 
mRNA from the nucleus to the cytoplasm through interactions with rev.   
Lentiviral Gene Regulation 
 CAEV and Visna Virus replication is tightly regulated and usually divided into two 
phases: early and late (Figure 5).  The early phase begins when the virus gains entry into a host 
cell by binding to the host cell receptors with its envelope glycoproteins.  The virus is then 
partially uncoated and the viral RNA is reverse transcribed producing a ds-DNA (double 
stranded DNA) copy of the viral genome (called the provirus) that is subsequently integrated into 
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the host cell genome.  Transcription of the viral genome in the host cell results in the production 
of three types of RNA:  Unspliced, singly spliced, and multiply spliced mRNAs (Figure 6).  The 
multiply spliced mRNAs, which contain rev and tat, are then transported to the cytoplasm and 
translated while the unspliced and singly-spliced mRNAs remain trapped in the nucleus.  The Tat 
protein then upregulates the expression of the viral mRNAs until a critical level of the Rev 
protein is reached (Clements and Zink 1996).  The late phase of viral gene expression can now 
begin and it includes the transport and translation of the unspliced and singly spliced mRNAs 
Gag, Pol, and Env.   
The unspliced and singly spliced mRNAs contain a stem-loop structure called the Rev 
Response Element (RRE).  This element is necessary for transport of the mRNAs to the 
cytoplasm.  The Rev protein returns to the nucleus from the cytoplasm to bind to the RRE.  This 
complex is then bound by the cellular proteins eIF-5A (eukaryotic initiation factor 5A), CRM1 
and RanGTP among others.  CRM1 or exportin 1 is the export receptor for Rev and it complexes 
with RanGTP in the presence of a NES (Nuclear Export Signal) (Pollard and Malim 1998).  The 
resulting complex of mRNA/RRE/Rev/CRM1/NES/RanGTP is then competent for transport 
through the NPC (Nuclear Pore Complex) (ibid).  After the mRNA complex reaches the 
cytoplasm, it disassembles and the mRNAs are translated to produce Gag, Pol, and Env proteins.  
The Rev protein returns to the nucleus to bind other RREs of unspliced and singly spliced 
mRNAs for transport to the cytoplasm.  The presence of both rev and the RRE are absolutely 
necessary for the completion of viral replication.  If either of the two is missing, then viral 
replication cannot be completed (Clements and Zink 1996, Luciw 1996, Pollard and Malim 
1998). 
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Figure 5.  Lentiviral Gene Regulation. 
 
AAAA7mG
AAAA7mG
AAAA7mGGag/Pol
Env
Rev  
 
Figure 6.  The Three Classes of mRNAs Produced by CAEV and Visna Virus.  The solid lines 
represent exons and the dashed lines represent the introns that are removed during splicing.  The 
stem loop structure represents the RRE that is only present in unspliced and singly spliced 
mRNAs.   
 
 17 
CAEV and Visna Virus Rev Protein 
 
 The CAEV Rev protein (Rev-C) has a molecular weight of about 18 KiloDaltons (kDa), 
while the Visna Virus Rev protein (Rev-V) has a molecular weight of about 22.5 kDa (Saltarelli 
et al. 1994, Schoborg and Clements 1994).  The amino acid sequences of Rev-C and Rev-V 
share little homology when compared to each other, except in two major domain regions:  the 
basic domain and the leucine rich domain or NES (Nuclear Export Signal) (Figure 7) (Tiley and 
Cullen 1992, Saltarelli et al. 1994, Schoborg et al. 1994).  The overall function of Rev is the 
same in both viruses and is the result of the two conserved domains.  The basic domain is located 
near the amino-terminal end of the protein and is rich in arginine residues.  It contains the 
Nuclear Localization Signal (NLS) and the RNA-binding domain (RBD) that is responsible for 
Rev binding to the RRE.  The basic domain is flanked on both sides by the sequences necessary 
for Rev multimerization (Clements and Zink 1996).  Mutations involving the arginine residues of 
this domain results in a Rev protein unable to bind the RRE or localize to the nucleus (Tiley and 
Cullen 1992, Schoborg and Clements 1994, Pollard and Malim 1998).  The leucine-rich domain, 
or Nuclear Export Signal, is located at the carboxy-terminal end of the protein.  Mutations in this 
domain do not affect Revs ability to localize to the nucleus or its ability to bind the RRE, but 
they do diminish Revs trans-activation ability (Saltarelli et al. 1994, Pollard and Malim 1998).  
Some leucine-rich domain mutants express a dominant negative phenotype and it has therefore 
been proposed that the leucine-rich domain interacts with the cellular proteins required for trans-
activation (Pollard and Malim 1998).   A critical level of Rev must be reached in the cytoplasm 
before the shift from early phase to late phase gene expression can occur (Schoborg et al. 1994, 
Clements and Zink 1996).  This is necessary because of the need for Rev to multimerize before 
transporting RRE containing mRNAs from the nucleus to the cytoplasm.   
Rev Toxicity 
Miyazaki et al. have demonstrated HIV-1 Rev is toxic to cultured cells (1995).  In addition they 
showed that the toxic effect mapped to the basic domain and required nuclear localization, as 
 18 
mutants with the basic domain which are nuclear transport defective do not have a cytotoxic 
effect (ibid).  The basic domain of HIV-1 Rev has also been shown to have a neurotoxic effect in 
mice (Mabrouk et al. 1991).  Previous experiments in our laboratory have suggested that Rev-C 
is also toxic when expressed in mammalian cells.  In these experiments, we were unable to 
isolate stable cell lines expressing any Rev protein with an intact basic domain (Table 1).  These 
results suggest that this toxicity is due to the basic domain of Rev.  Because HIV-1 Rev causes 
neurotoxicity in mice, Rev-C may be responsible for the neural pathogenesis of CAEV.  If the 
basic domain is responsible for the toxicity, then we may be able to design a treatment to reduce 
the pathology.  
 
 
47    90
135  SAQKEKR  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   156KGGLSGQRTNAYPGK
Rev-V
1      MDAGARYMRLTGKENWVEVTMDGEKERKREGFTAGQQDIQNSKY   44
45    PDIPTGHSHHGN SDSTES     90KSRRRRRKSGFWRWLRGIRQQRNKRK LE
91    EGAMEKGPAEAARP  . .   133PCLGALAELTL SADDGNLDKWMAWRTPQK
Rev-C
     MASKESKPSRTTRRDMEPPLRETWNQVLQELVKRQQQEEEEQQGLV
    SGLQASKADQIYTGNSGDRTTGGIGGKTKKKRGWYKWLRKLRAR
91    NIPSQFYPNMESN TQLEDDMAMDGREWMEWRE   134EK MVGMENLTLE
 
 
Figure 7.  Amino Acid Sequence of CAEV Rev (Rev-C) and Visna Virus Rev (Rev-V).  The 
Basic Domains are in green and the Leucine Domains (NES) are in red.  The C-terminal 
sequences are in purple (used to generate the Rev-V and Rev-C antibodies). 
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TABLE 1.  Toxicity of Rev-C Mutants in Cells   
 
% (number/total #) of cell lines positive, weakly positive 
and negative2 
Rev-C Protein 
Expressed1 
 
+3 
 
+/-3 
 
-3 
Rev-C wildtype 0% (0/42) 19% (8/42) 81% (34/42) 
Rev-C Delta Leu Rich  0% (0/33) 9% (3/33) 91% (30/33) 
Rev-C RR-DL 78% (28/36) 6% (2/36) 16% (6/36) 
Rev-C Delta Basic 61% (17/28) 11% (3/28) 28% (8/28) 
 
      [From Dr. Robert Schoborg unpublished results] 
 
1Rev expressing plasmids (described in Figure 13) were constructed by inserting various Rev 
encoding cDNA cassettes into the vector pMSG (Pharmacia) downstream from the MMTV LTR.  
The plasmid also contains a neomycin resistance gene which allowed G418 selection of stably 
transfected Cos-1 cell lines. 
2Cell lines were determined to be positive (+), weakly positive (+/-) or negative for Rev 
expression by 35S-labeling and immunoprecipitation with Rev-C specific serum after 
dexamethasone induction.  A positive signal was a Rev band easily visible on an overnight 
exposure and a weakly positive was a Rev band that was visible only after a 5 day exposure.  A 
cell line was judged negative if no Rev-specific band was visible after a two week exposure. 
3All positive and weakly positive cell lines were also subjected to immunofluorescence analysis 
after dexamethasone induction.  All positive cell lines were strongly positive in this assay; all 
weakly positive cell lines were negative.  Random negative cell lines were also tested; they were 
all negative in this assay. 
 
CAEV and Visna Virus Rev Response Element 
 The CAEV Rev Response Element (RRE-C) is located between the nucleotides 7907 and 
8108 while the Visna Virus Rev Response Element (RRE-V) is located between the nucleotides 
7923 and 8124 (Saltarelli et al. 1990, Tiley and Cullen 1992).  Computer analysis predicts that 
RRE-C and RRE-V have similar structures.  Figure 8 shows the secondary structure of the RRE-
V.  HIV-1 Rev has been shown to specifically bind with high affinity to a 13 nucleotide (nt.) 
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sequence in stem-loop II of its RRE.  The high affinity site must be bound by one Rev molecule 
first, and then additional Rev molecules can bind lower affinity sites on the RRE (Malim and 
Cullen 1991, Luciw 1996).  If the high affinity site in stem-loop II is mutated, then in vitro 
binding by Rev and trans-activation of RNAs by Rev are eliminated (ibid).  
 
 
 
 
Figure 8.  The Structure of the Visna Virus Rev Response Element (RRE-V).  This structure is 
similar to the RRE structure found in CAEV (RRE-C).  The darker line represents the minimal 
amino acid sequence needed to bind Rev-V (nt. 48-169).  Reprinted from Tiley and Cullen, 
Journal of Virology, Vol. 66, p. 3609-3615.   
 
  
Computer analysis has shown the RRE-V can be folded into two stable, but different 
secondary structures (Tiley and Cullen 1992).  The real RRE-V has been shown to be located 
between nucleotides 7923 and 8124 (RRE-V 7923-8124) based on Rev-V binding and cis-acting 
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experiments.  RRE-V8001-8202, which is located between nucleotides 8001and 8202, does not bind 
Rev-V in vitro and does not cis-activate RNA transport (ibid).  It is used in our experiments as a 
negative control.   
Like many sequences found in the lentiviruses, there is little amino acid sequence 
homology between the different virus strains for either Rev or the RRE.  However, the 
functionality and overall structure of both the proteins is conserved between the different strains.  
For example, it has been shown that the HIV-1 Rev can trans-activate RRE-C at 20% the level 
that Rev-C can, while Rev-V and Bovine Leukemia Virus Rex (Rex-B) trans-activate at only 
about 10% the level of Rev-C (Saltarelli et al. 1994).  Several groups have also shown that HIV 
and SIV Rev proteins will trans-activate thru the RREs of other strains with varying efficiencies 
(Malim et al. 1989, Sakai et al. 1991, Sakai et al. 1993, Hua et al. 1996).  It is likely that studying 
the trans-activation of Revs from different lentiviruses in detail will unmask previously 
unrecognized structural requirements for Rev/RRE binding and function. 
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CHAPTER 2 
EXPERIMENTAL APPROACH 
 
 As mentioned earlier, the HIV-1 Rev protein has been implicated for 
neurotoxicity in mice (Mabrouk 1991) and the CAEV Rev protein is thought to be toxic in 
mammalian cells.  The basic domain of Rev-C was implicated as the toxic element in those 
experiments.  In experiments involving transfections of Rev-C mutants, approximately 70% of 
the cell lines expressing Rev-C basic domain mutants expressed Rev strongly, while those 
containing leucine domain mutants and the wildtype Rev-C did not express Rev well (Table 1).  
The leucine domain (NES) mutants and the wildtype Rev-C contained the un-mutated basic 
domain which led us to the conclusion that the basic domain may be a toxic element.  If the basic 
domain is toxic to cells, then perhaps it can be used as a way to inhibit lentiviral replication in 
cells or to develop treatment programs to reduce the effects of the neurotoxicity of CAEV on 
animals.     
Another possible way to inhibit lentiviral replication is by overexpressing copies of the 
RRE.  The copies might act as decoys and bind Rev resulting in the inhibition of Rev and thus 
Env expression.  Overexpression of HIV-1 RREs in culture has been shown by several groups to 
inhibit HIV-1 replication (Lee et al. 1994, Bahner et al. 1996, Cullen 1998).  This has led to the 
thought that overexpression of RRE-V might inhibit the replication of visna virus in culture.  
Previous experiments in the Schoborg lab have shown that RRE-V can inhibit Env-V expression 
by up to 80% and visna virus replication by up to 85% in cell culture.  We wanted to improve on 
the 85% inhibition of viral replication, so it was necessary to develop better inhibitors.  We 
hypothesized that the addition of an ORF to the RRE expression plasmids would stabilize the 
decoy RNA so the inhibitor RNAs would stay around longer and work better.  In adddition, HIV-
1 studies have shown that SELEX can be used to select RNA ligands that will bind to Rev at 
least 10 times better than the wildtype RRE (Giver et al. 1993a, Giver et al. 1993b, Jensen et al. 
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1994, Jensen et al. 1995).  As a result, we hypothesized that we can use SELEX to make RNA 
ligands that will bind Rev-V better than RRE-V and that these aptamers will prove to be stronger 
inhibitors of Rev function than the RRE-V decoy. 
It has been shown on numerous occasions that lentiviruses can cross-activate across 
species.  In particular, it has been shown that RRE-C can be cross-activated by many different 
Rev proteins including HIV-1 Rev and Rev-V, although at decreased levels (Saltarelli et al. 
1994).  Previous experiments in the Schoborg lab have also suggested that the RRE-V can be 
cross-activated by Rev-C (Hansen 2001).  These results led to the hypothesis that Rev-C would 
cross-activate RRE-V but at a lower rate than it does RRE-C.  If this is true, then it could mean 
that an RRE-V decoy might also be able to work as a decoy inhibitor of other related 
lentiviruses.   
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Hypothesis 1 
The Rev-C basic domain mutants, Delta Basic and RR-DL, will be less toxic to cultured 
cells than the wildtype Rev-C and the leucine domain mutants, Delta Leu-Rich and LL-FV.   
 
Experimental Design 1 
A brief description of the experimental approach used to test this hypothesis is shown in 
Figure 9. 
 
Transfections using the six pTracer expression plasmids (Figure 13) into Cos-1 cells 
⇓ 
On days 3, 6, 12, 18, 24 and 30 perform FACS 
⇓ 
Perform statistical analysis using the WinMDI program 
⇓ 
Determine if any of the Rev-C basic domain mutants are less toxic than the wildtype Rev-C or 
the Rev-C leucine domain mutants 
 
Figure 9.  Summary of Experimental Design 1.    
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Hypothesis 2 
Overexpression of exogenous RRE-V will inhibit Rev function and thus Env expression 
by acting as a decoy for Rev binding. 
Experimental Design 2 
A brief description of the experimental approaches used to test this hypothesis is shown 
in Figure 10. 
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       Part 1:             Part 2: 
 
 Construct Hygromycin resistant   Transfect Cos-1 cells with Hygromycin 
 GFP/RRE-V expression plasmids  resistant plasmids expressing either 
      GFP/RRE-V, GFP/RNA-V, GFP/RRE-C 
      or GFP alone (Figure 15) 
   
                       ⇓      ⇓ 
 
 Co-Transfect pENV/L+ indicator   Culture cells to produce cell lines 
 plasmid with RRE-V expressing   expressing the Hygromycin resistant 
 plasmids into Cos-1 cells   plasmids 
        ⇓ 
 
Transfect cell lines with the indicator 
constructs pEnv/L+ and p1772  
 
           ⇓      ⇓ 
 
35S label transfected Cos-1 cells and collect lysates 
 
⇓ 
Perform TCA precipitations and quantitate lysates 
 
⇓ 
Immunoprecipitate Env-V and Rev-V from S35 lysates 
 
⇓ 
Electrophorese immunoprecipitations on SDS-PAGE gels 
 
⇓ 
Perform phosporimage analysis to quantitate Env-V and Rev-V expression 
       
⇓ 
Perform statistical analysis of results 
 
⇓ 
Determine if overexpression of exogenous RRE-V is able to act as a decoy and 
bind Rev-V thereby inhibiting Env expression. 
 
Figure 10.  Summary of Experimental Design 2. 
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Hypothesis 3 
RRE-V ligands that have a higher affinity for Rev-V than the wildtype RRE-V can be 
used as decoys to inhibit Rev-V function and viral replication. 
Experimental Design 3 
A brief description of the experimental approach is shown in Figure 11. 
 
 Construct a 60nt oligo with a randomly produced 30 nt. sequence in the middle and PCR 
amplify  
 
⇓ 
In vitro transcribe the DNA to produce RNA 
 
⇓ 
RNA binding to GST and Rev-V GST fusion proteins 
 
⇓ 
Reverse transcription of the bound RNA to produce DNA 
 
⇓ 
PCR amplification of the DNA 
 
⇓ 
One round of SELEX has been completed, repeat until nine rounds have been completed 
 
⇓ 
RNA binding assays comparing the wildtype RRE-V and the SELEX RRE-V transcript 
 
⇓ 
Electrophorese samples on 6% and 12% Urea/Polyacrylamide gels 
 
⇓ 
Competition RNA binding assays comparing wt. RRE-V and the SELEX RRE-V transcript 
 
⇓ 
Electrophorese samples on 3% NuSieve formaldehyde gels 
 
⇓ 
Determine if the SELEX RRE-V ligand is a better binder to Rev-V than the wildtype RRE-V 
 
Figure 11.  Summary of Experimental Design 3. 
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Hypothesis 4 
Rev-C will trans-activate through the RRE-V, but at a lower efficiency than Rev-V.  The 
lower efficiency is because it does not bind as well to RRE-V.  
Experimental Design 4 
A brief description of the experimental approach used to test this hypothesis is shown in 
Figure 12. 
 
Part 1: 
Co-Transfect pEnv/L(-) indicator plasmid with Rev-V, Rev-C, and a mock  (Figure 24) into  
Cos-1 cells  
 
⇓ 
 
35S label transfected Cos-1 cells and collect lysates 
⇓ 
Perform TCA precipitations and quantitate lysates 
⇓ 
Immunoprecipitate Env-V and Rev-V from 35S lysates 
⇓ 
Electrophorese immunoprecipitations on SDS-PAGE gels 
⇓ 
Perform phosporimage analysis to quantitate Env-V and Rev-V expression 
⇓ 
Perform statistical analysis of results 
⇓ 
Determine if Rev-C does activate RRE-V, but at a lower activation rate than Rev-V 
 
Figure 12.  Summary of Experimental Design 4. 
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Part 2: 
In vitro translate Rev-V, Rev-C (+) and Rev-C (-) with 35S 
⇓ 
Perform RNA binding assays using 32P labeled RRE-V, RRE-C (+) and RRE-C(-) 
⇓ 
Electrophorese RNA binding assays on 6% urea/polyacrylamide gels 
⇓ 
Perform phosporimage analysis to quantitate Rev-C's affinity for RRE-V 
⇓ 
Perform statistical analysis 
⇓ 
 Determine if the reason for a decrease in Rev-C's ability to activate RRE-V is because it does 
not bind RRE-V as well 
 
 
Figure 12 (continued). 
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CHAPTER 3 
MATERIALS AND METHODS 
 
Bacterial Strains 
 GST and GST-Rev-V cell lysates were isolated from BL21 E. coli, which was a gift from 
Dr. Bryan Cullen (Malim and Cullen 1991).   
Cell Lines 
 Cos-1 cells were used in all procedures requiring cell culture.  Cos-1 are derived from 
simian kidney cell lines that were transformed with the SV40 T antigen.  They were maintained 
in Dulbeccos Modified Eagle Medium (GlutaMAX 1 + high glucose + 25 mM HEPES buffer + 
pyridoxine HCL) (Life Technologies) + 10% heat inactivated Fetal Bovine Serum (Atlanta 
Biologicals) + 10 mM MEM Sodium Pyruvate Solution (Life Technologies) + 0.05mg/ml 
Gentamycin (Cellgro) + 1ug/ml Fungizone (Life Technologies).    
Antibodies 
 Several different antibodies were used in these projects.  Rabbit polyclonal Rev-C 
antisera was used in the Rev-C/ RRE binding assays.  It is directed against the final 19 carboxy-
terminus amino acids (SADDGNLDKWMAWRTPQ) of Rev-C (Saltarelli et al. 1994).  Affinity 
purified Rev-C antisera was used in all other experiments.  Rabbit polyclonal Rev-V antisera was 
used in the Rev-V/ RRE binding assays.  Affinity purified Rev-V antisera was used in all other 
experiments.  It is directed against the final 15 carboxy-terminus amino acids 
(KGGLSGQRTNAYPGK) of Rev-V (Schoborg and Clements 1994).  Antibody to Env-V (visna 
Env) was provided by Dr. Andrés de la Concha-Bermejillo (Texas A & M University). 
Rev-C Expression Plasmids 
 There were several Rev-C expression plasmids used to work on the Rev Toxicity project.  
They were made by using the indicator construct pTracer which expresses the green fluorescent 
protein (GFP) that was used to identify plasmid carrying cells through FACS analysis.  In these 
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plasmids, the CMV IE promoter expresses the GFP protein and the SV40 early promoter 
expresses the Rev-C proteins.  All of these plasmids have been sequenced and shown to express 
the appropriate Rev protein at similar levels (data not shown).   
 
CMV IE Poly A
GFP
SV40
Rev-C
Tracer Rev-CP
CMV IE Poly A
GFP
SV40
Tracer P
Rev-C wt                        GNKSRRRRRKSGFWRWLRGIRQQRNKRKSDSTES
Rev-C RR-DL               GNKSRDLRRKSGFWRWLRGIRQQRNKRKSDSTES
Rev-C Delta Basic         GNKS-----------------------------------------------------SDSTES
Rev-C wt                         GALAELTLEGAMEKGP
Rev-C LL-FV                 GALAEFTVEGAMEKGP 
Rev-C Delta Leu-Rich   GALAE-----------------KGP 
A.
B.
 
Figure 13.  Rev-C/GFP Expression Constructs.  A.) pTracer indicator construct alone and 
pTracer indicator construct with the Rev-C expression casette inserted.  B.) Diagram showing 
where the different mutations were made in the basic and leucine domains to produce the Rev-C 
mutants.   
 
Transformations 
 Epicurean Coli XL-1 Blue MRF supercompetent cells (Stratagene) were first thawed on 
ice and then 100 ul were aliquoted into sterile, chilled on ice, 17 X 100 mM polypropylene tubes 
(Fisher).  One point seven ul of  β−mercaptoethanol was added to each tube, followed by gentle 
mixing and then incubation of the tubes on ice for 10 minutes mixing every 2 minutes.  One ul of 
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plasmid DNA or 3 ul of ligation mix was added to this reaction tube.  The tubes were gently 
mixed and placed on ice for 30 minutes.   This was followed by 45 seconds in a 42°C water bath 
and then placed back on ice for 2 minutes.  Nine hundred ul of SOC media (2% bacto-tryptone, 
0.5% bacto-yeast extract, 0.05% NaCl, 20 mM glucose) was then added to each tube followed by 
an hour incubation at 37°C while shaking at about 225 rpm. 
Antibiotic Selection of Transformants  
 Transformed cells were plated on L Broth agar plates (1.0% NaCL, 1.0% bacto-tryptone, 
0.5% bacto-yeast extract, 1.5% bacto-agar) using the appropriate antibiotic.  The pTracer based 
plasmids required 250 ug/ml Zeocin and all ligation transformations required 50 ug/ml 
Ampicillin per plate.  The pTracer plasmid transformations were plated out on 3 plates at 
different volumes: 1 ul, 5 ul and 10 ul.  The ligation transformations were plated out on 4 plates 
at volumes of 10 ul, 25 ul, 50 ul, and 100 ul.  The plates were incubated overnight at 37°C.   
Mini-Prep 
 Followed laboratory protocol as described by Dr. Michelle Abelson (2000). 
Large Scale Plasmid Preparations 
 The Concert High Purity Plasmid Maxiprep kit purchased from Life Technologies, was 
used to do large scale preparations of DNA.  The manufacturers directions were followed 
completely.  Upon completion of the plasmid prep, the concentration of each DNA was acquired 
by diluting each 1:200 in double distilled water (ddH20) and measuring its optical density at both 
260nm and 280nm wavelengths using the Spectronic Spec 600  Spectrophotometer.  Using the 
resulting 260 optical density (OD), the amount of DNA was calculated as follows:  OD260 X 50 
(conversion factor) X 200 (dilution factor) / 1000 ul = ug/ul.  The plasmid preps were then 
checked for purity and positive identification by restriction digests followed by electrophoresis 
on an agarose gel with known standards.  The plasmids were then stored at -20°C.  
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EtOH Precipitation of DNA for Transfection 
 Before every transfection, the DNAs were purified by 3M NaOAc / Ethanol (EtOH) 
precipitation.  To the volume of any DNA, the following was added:  1/10 volume of 3M NaOAc 
pH 5.2  and 2 X volume of 95% EtOH.   They were vortexed and stored at -80°C for one hour.  
Samples were then centrifuged at 12,000 rpm, 4°C for 15 minutes.  The supernatants were 
discarded and the pellets were washed 2 X with 1 ml of 70% EtOH, vortexed and centrifuged at 
12,000 rpm, 4°C for 5 minutes.  Supernatants were removed and the pellets were dried for 5-10 
minutes in the speed vac.  The pellets were then resuspended in nuclease free H2O and frozen at -
20°C. 
Transfection of Mammalian Cells 
 We used 2 different transfection protocols:  Lipofectin/OPTI-MEM 1 and TransIT-LT1.  
Transfections were done in Cos-1 cells plated at a density of 4.5 X 105 cells per well in 4 mls of 
media in a 6 well plate (Costar) or 2.5 X 106 cells in 100 mM plates (Corning) in 10 mls of 
media.  The lipofectin/OPTI-MEM 1 transfections were set up in 15 ml Polystyrene tubes 
(Fisher).  For each transfection 75 ul of lipofectin and 300 ul OPTI-MEM 1 reduced serum 
medium [MEM (high glucose + 25 mM HEPES buffer + pyridoxine HCL) + 1 X HEPES buffer 
+ 2.4 mg/ml sodium bicarbonate + L- glutatmine] (Life Technologies) was added to 1 
polystyrene tube and incubated at RT° for 40 minutes.  Each DNA to be transfected was added to 
600 ul of OPTI-MEM 1 in a polystyrene tube and then sterile filtered into a new polystyrene tube 
(using a sterile cameo filter and a 1 ml syringe).  Six hundred microliters of the lipofectin/OPTI-
MEM 1 mix was then added to the DNA/OPTI-MEM 1 mix and incubated for 10 minutes at 
RT°.  During the 10 minute incubation time period, each of the 100 mm plates of Cos cells had 
the media aspirated and re-fed with 6 mls of OPTI-MEM 1.   To each DNA/OPTI-MEM 
1/lipofectin mix, 3.3 mls of OPTI-MEM 1 were added to bring the total volume of transfection 
mix up to 4.5mls.  The OPTI-MEM 1 was then aspirated from each plate and the 4.5 mls of 
transfection mix was added to each plate.  Each plate was then swirled to mix and placed in the 
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incubator (37°C with 5% CO2) for 6-8 hours.  The plates were then removed from the incubator, 
the transfection mix was aspirated, and the cells were re-fed with 10 mls of media and placed 
back into the incubator.  
 Transfections done with TransIT-LT1 were set up in sterile 1.5 ml screw cap tubes.  For 
each reaction 100 ul OPTI-MEM 1 + 6 ul TransIT-LT1 were added to each tube, gently mixed, 
and incubated at RT° for 20 minutes.  Two ug of DNA was added for each reaction to the 
appropriate tube, gently mixed, and incubated at RT° for 20 minutes.  The media was aspirated 
from each well of the plated Cos-1 cells (in 6 well plates) and the cells were re-fed with 2 mls of 
media.  The DNA/OPTI-MEM/TransIT-LT1 mix was then added drop-wise to the appropriate 
well.  The plates were swirled to mix and then placed in the incubator until ready for labeling.   
Preparation of Cells for FACS 
 Transfected COS-1 cells expressing GFP were harvested and prepared for FACS 
(Fluorescent Activated Cell Sorter) by first aspirating the media from each well and placing it 
into a labeled 15ml polypropylene tube (Fisher) on ice.  Each well was then washed  twice with 3 
mls of 1 X PBS (Phosphate Buffered Saline).  Zero point five ml of 1 X Trypsin (Life 
Technologies) was then added to each well and then removed.  The 6 well plate was then placed 
into the incubator for 3-5 minutes.  The original supernatant from each well was then added back 
to its well and washed up and down in the pipette until all cells were lifted from the well.  The 
cells/supernatant were then placed back into the 15 ml polypropylene tube and put back onto ice.  
A serum cushion was then added to each tube by using a plugged Pasteur pipette to carefully add 
approximately 0.5 ml of 10% FCS (Fetal Calf Serum) to the bottom of the tube so that a cushion 
was formed and then it was placed back on ice.  The tubes were centrifuged at 1500 rpm for 5 
minutes at 4°C.  An unplugged pipette was used to aspirate off the supernatant down to the pellet 
and the pellet was then resuspended in 1 ml 1 X PBS/ 5mM EDTA.  The mix was pipetted up 
and down and then moved into a 1.5 ml flip top tube.  The tubes were centrifuged for 3 minutes 
at 2000 rpm at 4°C.  The supernatant was aspirated off down to the pellet and the pellet was then 
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resuspended in 1 ml 1 X PBS/ 5mM EDTA.  The mix was filtered through Spectra/Mesh 
Polypropylene filter (105 um opening, 20% open area, 212 um thick, stock # 146 436) into a 5 
ml Flow Cytometry tube provided by Scott Reynolds and then placed on ice.  The samples then 
had FACS analysis (Becton Dickson FACScan) performed on them by Scott Reynolds.  The 
resulting data were analyzed using the WinMDI program. 
Gel Purification of DNA and Ligations 
 Followed laboratory protocol as described by Dr. Michelle Abelson (2000).  
35S Labeling and Harvesting of Cos-1 Cells, TCA Precipitation and Quantification of 35S Labeled 
Cell Lysates, and Immunoprecipitation of Env and Rev Proteins 
 Followed laboratory protocol as described by Lillia Holmes (1997). 
Gel Electrophoresis 
Several types of gel electorphoresis were used while performing these experiments.  They 
are SDS PAGE, urea/polyacrylamide, and formaldehyde gels.  SDS PAGE gels were run to 
quantitate immunoprecipitations and protein expression.  Samples were boiled for 10 minutes, 
quenched on ice, and centrifuged briefly.  Rev immunoprecipitations were electrophoresed on 
SDS PAGE gels that included a 15% running gel (6 ml 37:5:1 acrylamide/bis (AMRESCO), 5 ml 
ddH20, 3.75 ml 1.5 M Tris pH 8.8, 0.15 10% SDS, 0.15 ml 10% APS, 0.75 g Sucrose, 5 ul 
TEMED) and a 5% stacking gel (1.3 ml 37:5:1 acrylamide/bis, 6 ml ddH20, 2.5 ml 0.5 M Tris 
pH 6.8, 0.1 ml 10% SDS, 0.1 ml 10% APS, 10 ul TEMED).  Env immunoprecipitations were 
electrophoresed on SDS PAGE gels that included a 10% running gel (4 ml 37:5:1 acrylamide/bis 
(AMRESCO), 7 ml ddH20, 3.75 ml 1.5 M Tris pH 8.8, 0.15 10% SDS, 0.15 ml 10% APS, 0.75 g 
Sucrose, 5 ul TEMED) and a 5% stacking gel.   The gels were run in 1 X Tris/Glycine E buffer 
(25mM Tris, 250 mM Glycine, 0.1%SDS) on either a Hoeffer SE 600 Gel apparatus or a BioRad 
Mini PROTEAN 3 apparatus.  The gels were run at 100 volts until the dye front passed through 
the stacking gel and then the voltage was turned up to 300 volts.  The gels were run until the dye 
front reached the bottom, they were then removed and placed in protein gel fixer (30% methanol, 
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10% acetic acid) for 30 minutes, and then fluorographed with Entensify solutions A and B 
(DuPont/NEN Research Products) for 30 minutes in each solution.  The gels were then dried for 
3 hours on a vacuum gel dryer at 65°C, placed on a phosphor screen for later quantification 
analysis and then put up on x-ray film (Kodak) with intensifying screens at -70°C.  
Phosporimaging analysis was done using a BioRad FX imager with Quantity One software v2.4.   
Binding assays and RNA samples were run on 6% and 12% urea/polyacrylamide gels.  
The samples were resuspended in sequencing dye (For 10 mls: 10 ml deionized formamide + 5 
mg xylene cyanol + 5 mg bromophenol blue + 200 ul 0.5 M EDTA).  These gels were run on 
either the Hoeffer or the BioRad apparatii.  Samples were boiled for 10 minutes, quenched on 
ice, and centrifuged briefly.  They were then electrophoresed on either a 6% urea/polyacrylamide 
(for 200 mls:  96 g Urea + 30 mls 19:1 acrylamide/bis (AMRESCO) + 40 mls 5 X TBE) or a 
12% urea/polyacrylamide gel (for 200 mls:  192 g Urea + 30 mls 19:1 acrylamide/bis 
(AMRESCO) + 40 mls 5 X TBE).  The gels were run at 300 volts until the second dye front 
reached the bottom, they were then removed and placed in sequencing gel fixer (20% methanol, 
10% acetic acid) for 30 minutes.  The gels were then dried for 3 hours on a vacuum gel dryer at 
65°C, placed on a phosphor screen screen for later quantification analysis and then put up on x-
ray film (Kodak) with intensifying screens at -70°C.  Phosporimaging analysis was done using a 
BioRad FX imager with Quantity One software v2.4.  RNA binding assays were run on 1% 
MOPS formaldehyde gels.  Samples were resuspended in a sample buffer made up of:  1 ug 
RNA + DEPC H20 up to 2.25 ul + 1 ul 10 X MOPS, 1.75 formaldehyde + 5 ul deionized 
formamide + 1ul EtBr.  Samples were heated to 55°C for 10 min and then 2 ul RNA loading dye 
were added to each sample.  Samples were then immediately loaded onto the MOPS 
formaldehyde gel (for 80 mls:  57.6 mls DEPC H20 + 0.8 g agarose + 8 ml 10 X MOPS, that was 
heated and cooled, followed by the addition of 14.4 mls formaldehyde).  The gels were 
electrophoresed (in 1 X MOPS buffer) at 55 volts for 6-8 hours, removed, placed on the vacuum 
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gel dryer for 3 hours at 50°C, placed on a phosphor screen for later quantification analysis, and 
then put up on x-ray film (Fuji Safelight) with intensifying screens at -70°C.   
Phenol/Chisom Extractions 
  There were 2 methods used to phenol chisom extract samples throughout these 
experiments.  One method employed the use of phase lock tubes purchased from 5 Prime → 3 
Prime, Inc.  The manufacturer's instructions were followed to complete the extraction.  
Otherwise samples were phenol/chisom extracted by adding equal volume of phenol/chisom (1:1 
solution, chisom is 24:1 solution of chloroform and isoamyl alcohol), vortexing, and centrifuging 
for 3 minutes, 4°C at 12,000 rpm.  The aqueous layer (top layer) was removed to a new tube, an 
equal volume of chisom was added and the tube was vortexed and spun again.  This step was 
repeated and the aqueous layer was then EtOH precipitated, dried in the speed vac, and 
resuspended in the appropriate amount of H2O. 
In Vitro Transcription of 32P Labeled RREs 
 The following RREs were in vitro transcribed for various experiments:  RRE-V, RNA-V, 
RRE-C (+) and RRE-C (-).  Linearized DNA preparations of each pGEM RRE clone were first 
heated at 55°C for 10 minutes and then quenched on ice.  The reactions were set up in 1.5 ml 
screw cap tubes:  4 ul 5 X T7 or SP6 Polymerase buffer (which ever is required based on the 
promoter present in each DNA) (Promega) + 2 ul 100 mM DTT + 2 ul 5 mM ribonucleotides A, 
C and G + 2 ul 100 uM rUTP + 5 ul alpha 32P rUTP + 1 ul DNA template + 1 ul RNasin 
(400u/ul) (Promega) + 1 ul T7 or SP6 RNA Polymerase + 2 ul DEPC treated H2O.  The tubes 
were placed at 37°C for 1 hour, then 16 ul DEPC treated H2O was added along with 4 ul 5 X 
transcription buffer and 2 ul RQ1DNase (Promega).  The tubes were then placed at 37°C for 30 
minutes, phenol/chisom extracted, EtOH precipitated, dried in the speed vac, resuspended in 200 
ul DEPC treated H2O, counted, and stored at -20°C. 
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Construction of the Oligo Used to Make the SELEX RNA Aptamers 
 An oligo was designed to develop the random RNA ligands for the SELEX protocol.    
The oligo consisted of a SP6 promoter with 30 nt. of unknown nucleotides that was cloned into a 
pCR vector (T7 promoter) using the TA Cloning Kit by Invitrogen.  This resulted in a known 60 
nt. oligo with a T7 promoter sequence on the 5 end, a SP6 promoter sequence on the 3 end and 
a 30 nt. random sequence in the middle.  This was then PCR amplified using the T7 and SP6 
promoters and the DNA was then in vitro transcribed using T7 polymerase resulting in a pool of 
RNAs that had known terminal sequences and random interior sequences.   
SELEX:  Cell Lysate Preparation 
BL21 E.coli clones expressing GST or GST-Rev-V fusion protein were streaked onto L 
Broth agar plates (1.0% NaCL, 1.0% bacto-tryptone, 0.5% bacto-yeast extract, 1.5% bacto-agar) 
containing 50 ug/ml of Ampicillin and placed at 37°C overnight.  One isolated colony was 
selected from each plate and added to a sterile test tube along with 5 ml LB-Amp and then placed 
on a shaker at 200 rpm overnight at 37°C.  Each 5ml cell culture was then poured into a sterile 
1L flask with 500 ml LB-Amp and grown until the OD at 600nm reached 0.6 - 0.8.  Five hundred 
five ul of IPTG (100 mM) was then added to each flask and incubated for 90 minutes at 37°C  on 
a shaker.  The cells were harvested by pouring the contents of each 1L flask into 2, 500 ml 
centrifuge tubes followed by centrifugation for 10 minutes at 7,000 rpm.  The supernatant was 
discarded and 4.75 ml of TSE Buffer (50mM Tris pH 8.0 + 25%sucrose + 1mM EDTA) was 
added to the tubes.   The mix was then vortexed well to make a homogeneous suspension.   The 
suspension was transfered to Oak-ridge tubes (50 ml) and the following was added:  12 ul of 
PMSF (100mM), 5 ul Leupeptin (10mg/ml), 5 ul Pepstatin (10mg/ml) and 125 ul Lysozyme 
(20mg/ml).  The tubes were mixed well and then incubated at room temperature (RT) for 5 
minutes.  The following was then added to each tube:  32.5 ul 2M MgCl2, 6.5 ul 1M MnCl2, and 
6.5 ul DNase, mixed well and incubated in a 37°C water bath for 15 minutes.  Then we added the 
following:  850 ul 10X PBS, 425 ul 20 % Triton X-100, 425 ul Tween-20 and 85 ul 1M DTT, 
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mixed well, and then centrifuged tubes at 10,000 rpm for 10 minutes.  The cell lysates were 
transfered  to new Oak-ridge tubes and the lysate's volume was measured.  We added 10% of  the 
lysate's volume in glycerol, mixed well, aliquoted 550 ul of the lysate into 1.5 ml flip-top tubes, 
and stored at -20°C . 
SELEX:  Transcription 
The in vitro transcription was set up in a 1.5 ml screw-cap tube and the following 
reagents were added: 30 ul of cDNA, 28 ul DEPC treated water, 20 ul 5X transcription buffer, 10 
ul rNTP's, 10 ul 100 mM DTT, 0.4 ul 1 M MgCl2, and 1.6 ul SP6 polymerase for a total volume 
of 100 ul.  The tube was placed in a 37°C water bath for 2 hours and then 2 ul RQ1DNase was 
added and the tube was incubated for 30 minutes at 37°C  (water bath).  We removed 6 ul and 
put into 2 - 0.5 ml flip top tubes as 3 ul aliquots and added 1 ul RNase A (10mg/ml) to one tube 
and nothing to the other tube.   The 2 tubes were incubated at 37°C  (water bath) for 30 minutes. 
The 2 samples were then run out on a 1.5 % agarose gel TBE+EtBr with a 100 bp marker to 
ensure that RNA had been made.  There should not be a band seen in the Rnase A sample lane, 
but the other lane should show a 100 bp product.  We took the remaining volume from the in 
vitro transcription and did an organic solvent extraction (phenol/chisom extraction) by adding 
100 ul of DEPC treated water and transferring that volume (approximately 200 ul volume) to an 
already spun down (30 seconds) phase lock tube.  We then added the same volume (200 ul) of 
Phenol/chisom (for RNA use), inverted the tube and centrifuged the tube for two minutes at 
10,000 rpm.  Next we added 200 ul of Chisom (for RNA use), inverted the tube and centrifuged 
for 2 minutes at 10,000 rpm.  We repeated the last step again and then we removed the aqueous 
layer to a new 1.5 ml screw cap tube and measured its volume.  We then ethanol precipitated the 
RNA according to its volume and using RNA reagents and upon completion of the EtOH 
precipitation, the pellet was dried in the speed vacuum (Savant).  The RNA pellet was 
resuspended in 200 ul DEPC treated water, divided evenly into 2 screw cap tubes, and stored at -
80°C. 
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SELEX:  Binding 
One tube of GST-Rev-V cell lysate (Rounds 1-9) and 1 tube of GST cell lysate (Rounds 
5-9) were thawed at room temperature.  The cell lysates were divided between two 1.5 ml flip-
top tubes (250 ul each, total of 4 tubes if using both cell lysates).  We added the same volume of 
50 mM Tris pH 8.0 to each tube along with 25 ul of Glutathione agarose beads.  The tubes were 
placed on the rotator in the 4°C walk-in room for 30 minutes and then centrifuged at 4°C and 
12,000 rpm for 3 minutes.  The supernatants were discarded and the beads were washed 4 X with 
1 ml of 50 mM Tris pH 8.0.  Five hundred ul of 1X CH running modified buffer (For a 2 X 
solution of 500 mls:  453.5 ml DEPC treated water, 30 ml 5M NaCl2, 10 ml 1M Tris pH 8.0, 
0.0305 g MgCl2, and 6.5 ml BIACore NP-40) was added to the beads, and using a large orifice 
tip removed the beads from both tubes (2 tubes per cell lysate type) into one 1.5 ml screw cap 
tube (one tube per cell lysate type).  Another 500 ul of 1X CH running modified buffer was 
added to make sure all of the beads were removed.  The tubes were centrifuged at 4°C, 12,000 
rpm for 3 minutes and the supernatant was discarded.  For Rounds 1-4 (Worked with GST-Rev-
V tube only) we added 100 ul 1X CH running modified buffer + 100 ul in vitro transcribed RNA 
+ 4 ul Rnasin.  The tube was attached to a styrofoam rack which was attached to the vortex and 
then the tube was vortexed (lightly) continuously for 1 hour at a speed of 3 or 4 followed by 
centrifugation at 4°C, 12,000 rpm for 3 minutes.  (For Rounds 5-9: stored the GST-Rev-V tube 
at 4°C for later and initially work with the GST tube of beads by adding 100 ul 1X CH running 
modified buffer + 100 ul in vitro transcribed RNA + 4 ul Rnasin.  The tube was attached to a 
styrofoam rack which was attached to the vortex and then the tube was vortexed continuously for 
1 hour at a speed of 3 or 4 followed by centrifugation at 4°C, 12,000 rpm for 3 minutes.  The 
liquid from the beads was transferred to the GST-Rev-V tube of beads and that tube was attached 
to the styrofoam rack which was attached to the vortex and vortexed continuously for 1 hour at a 
speed of 3 or 4 followed by centrifugation at 4°C, 12,000 rpm for 3 minutes).  The supernatant 
was discarded and the bead were washed 6 X with 1 ml of 1X CH running modified buffer 
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followed by centrifugation at 4°C, 12,000 rpm for 3 minutes.  Four hundred ul of pre-warmed 
(62°C)  Proteinase K digestion buffer (for 1 ml:  780 ul of DEPC treated water, 20 ul of 1M 
Tris.Cl pH 7.5, 50 ul 0.4M EDTA pH 8.0, 50 ul 10% SDS and 100 ul of 10 mg/ml Proteinase K) 
was added to the tube and incubated at 62°C for 2 hours.  The tube was boiled for 5 minutes to 
release the bound RNA from the beads and then centrifuged at 4°C, 12,000 rpm for 3 minutes.  
The supernatant (approximately 400 ul volume) was transferred to an already spun down (30 
seconds) phase lock tube and a Phenol/Chisom extraction (follow protocol as done earlier) was 
done.  The aqueous layer was transferred to a 1.5 ml screw cap tube its volume was measured in 
order to EtOH precipitate the RNA as usual.  The pellet was dried for 5 minutes in the speed 
vaccuum and resuspended in 30 ul DEPC treated water.  This RNA was used to set up the RT 
(Reverse Transcriptase) reaction. 
SELEX:  Reverse Transcription 
Four 0.5 flip top tubes tubes were irradiated for 20 minutes before setting up the 
reactions.  We divided the 30 ul RNA sample resulting from the binding procedure into 3 tubes 
(10 ul in each tube) and added 1 ul of DEPC treated water to each tube.  A negative control using 
11 ul of DEPC treated water was set up.  One ul of primer SS (Sal-Sma selex) (1 ug/ul) was 
added to each tube, the tubes were placed at 70oC for 10 minutes and then quenched on ice.  Four 
ul 5X RT buffer (Promega) + 2 ul 0.1 M DTT  (Promega) + 1 ul 10 mM dNTP's  (Perkin Elmer) 
was added to each tube, mixed well and placed at 42oC for 2 minutes.  One ul RT enzyme (M-
MLV from Promega) was added to each tube and the tubes were placed at 42oC for 90 minutes 
and then transfered to 70oC for 15 minutes. They were centrifuged briefly and then the DNAs 
were ready for the PCR step. 
SELEX: PCR 
The negative control is the negative reaction tube from the previous RT reaction while 
the positive control is a dilution of the DNA SELEX template (1:25).  There are 11 reactions 
total (negative, positive, and three for each of the three RT reactions).  We added 78.8 ul of PCR 
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water to both the negative and positive control tubes and 73.3 ul of PCR water to each of the 
sample tubes.  We made a master mix with the following reagents (For 11 reactions: negative, 
positive, and three samples):  110 ul 10 X PCR buffer  (Perkin Elmer), 22 ul 10 mM dNTP's  
(Perkin Elmer), 66 ul 25 mM MgCl2  (Perkin Elmer), 5.5 ul primer SS (Sal-Sma selex), 7.7 ul 
primer SCH (SP6-Cla-Hind selex), and 11.0 ul Amplitaq Gold enzyme (Perkin Elmer).  We 
added 20.2 ul of the master mix to each tube.  We added 1 ul of the negative control from the 
previous RT reaction to the negative control tube, 1 ul of the 1:25 dilution of the DNA selex 
template to the positive control tube, and 6.5 ul from the each of the three previous RT reactions 
to the three sample tubes.  The tubes were placed in the thermocylcer and the program named 
"CAPCR" was run (PCR Cycle:  step # 1: 94°C for 30 seconds, step # 2: 65°C for 1 minute, step 
# 3: 68°C for 1 minute, step # 4: go to step # 1 for 39 cycles, step # 5: 68°C for 7 minutes, and 
step # 6: 4°C  overnight).   Five ul was removed from each tube and electrophoresed on a 1.5 % 
agarose gel TBE + EtBr along with a 100 bp marker.  If a 100 bp product was present in each 
sample lane and nothing was in the negative lane, then the 3 tubes from the reaction samples 
were pooled together and an organic solvent extraction was performed, but before starting the 
extraction a 5 ul aliquot of the pooled DNA was saved and stored at -20°C.  The remaining 
volume of DNA (approximately 280 ul volume) was transfered to an already spun down (30 
seconds) phase lock tube for the Phenol/Chisom extraction.  After the extraction was completed, 
the aqueous layer was removed to a 1.5 ml screw cap tube and the volume was measured in order 
to EtOH precipitate the RNA as usual.  The pellet was dried in the speed vaccuum, resuspended 
in 50ul DEPC treated water, and stored at-20°C.  One round of SELEX has been completed and 
the DNA is now ready for the next round of SELEX (9 total rounds were done).  
SELEX:  RNA Binding Assays 
These were done to determine the minimum amount of protein necessary for binding 
(saturation point of binding).  The SELEX binding reactions were done with 5 fold serial 
dilutions of GST-Rev-V.  The reactions were built in 1.5 ml screw cap tubes:  250 ul GST-Rev-
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V dilution + 250 ul 50 mM Tris pH 8.0 + 25 ul glutathione agarose beads (Amersham 
Pharmacia).  The tubes were attached to a rotator at 4°C for 30 minutes and then centrifuged for 
3 minutes 12,000 rpm at 4°C.  The supernatants were discarded and the beads were washed 4 
times with 1 ml 50 mM Tris pH 8.0 and then washed twice with 1 ml 1 X CH running buffer 
(centrifuged for 3 minutes 12,000 rpm at 4°C after each wash).  After the last wash, the 
supernatants were discarded and the pellets were resuspended in 100 ul 1 X CH running buffer + 
100 ul in vitro transcribed 32P RRE-V probe + 4 ul RNasin.  The tubes were attached to a vortex 
and vortexed at a speed of 3-4 for 1 hour followed by centrifugation for 3 minutes at 12,000 
rpmc 4°C.  The supernatants were discarded and the were pellets washed 6 times with 1 X CH 
running buffer and resuspended in 25 ul sequencing dye.  The samples were boiled for 10 
minutes, quenched on ice, centrifuged briefly, and run out on a 6% urea/polyacrylamide gel.   
SELEX:  Competition Assays 
Based on the results from the RNA binding assays, it was determined that a 1:125 
dilution of GST-Rev-V cell lysate would provide the minimum amount of protein needed to 
maximize the binding reaction.  We did one dilution of the cell lysate in a 50 ml conical tube (for 
16 reactions):  32 ul of GST-Rev-V + 3968 ul storage buffer (what the cell lysates were 
resuspended in for freezing) + 400 ul glutathione agarose beads + 4000 ul 50mM Tris pH 8.0.  
The tube was then placed on the rotator for 30 minutes at 4°C followed by centrifugation at 
5,000 rpm, 4°C, for 3 minutes.   The supernatant was discarded and the pellet was washed 4 
times with 5 ml 50mM Tris pH 8.0 and then washed twice with 5 ml 1 X CH running buffer 
(centrifuged each time at 5,000 rpm, 4°C, for 3 minutes).  After the final wash, the beads were 
resuspended in 1600 ul 1 X CH running buffer, mixed and 112 ul of beads/buffer was aliquoted 
into 14, 1.5 ml screw cap tubes.  Two sets of competition assays were done; one involving the 
unlabeled wildtype RRE and one involving the unlabeled RNA-V (negative control).  The 
competitor was diluted 5 fold over 5 dilutions.  There were 7 tubes for each assay (7 for RRE-V 
and 7 for the SELEX ligand):  Undiluted tube, 1:5 tube, 1:25 tube, 1:125 tube, 1:625 tube, 
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1:3125 tube, and a tube with no competitor (positive control).  To each tube 112 ul beads/CH 
buffer and 1 ul (2ug) of the appropriate competitor (1 ul DEPC H20 was added to the positive 
control) was added followed by 100 ul of a mix consisting of labeled RRE-V or SELEX ligand, 
DEPC H20 and RNasin (1,000,000 cpms of each probe + 2 ul RNasin + DEPC H20 up to 100 
ul).  The tubes were attached to a vortex and vortexed at a speed of 3-4 for 1 hour followed by 
centrifugation for 3 minutes at 12,000 rpm, 4°C.  The supernatants were discarded and the pellets 
were washed 6 times with 1 X CH running buffer and resuspended in 25 ul sequencing dye.  The 
samples were boiled for 10 minutes, quenched on ice, centrifuged briefly, and then 
electrophoresed on either a 6% urea/polyacrylamide gel (RRE-V samples) or a 12% 
urea/polyacrylamide gel (SELEX ligands). 
In Vitro Transcription,Translation and Immunoprecipitation of IVTs  
Followed laboratory protocol as described by Dr. Michelle Abelson (2000). 
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CHAPTER 4 
RESULTS HYPOTHESIS 1 
 
FACS Analysis of Cells Expressing Rev-C  
 Previous data in the lab had indicated that Rev-C is toxic when expressed in mammalian 
cells.  The basic domain had been implicated as the cause of the toxicity.  If this is true, then 
perhaps treatments can be devised to counteract the toxic effects of Rev in vivo.  To determine if 
the basic domain of Rev is acutely toxic, transfections were done in Cos-1 cells using 
pTracer/Rev-C mutant expression plasmids.  The transfections were done using the lipofectin 
method (described previously).  Three days post-transfection, we split the cells and performed 
FACS analysis on 20,000 cells; the remaining cells were replated in new media.  We split, FACS 
analyzed and replated the cells also on days 6, 12, 18, 24, and 30 post-transfection.  FACS 
analysis was done on the transfected cells to determine the number of GFP events from each time 
point.   A graph was produced based on the WinMDI analysis of each time point as shown in 
Figure 14.    
 Based on the graphical analysis done, it apppears that there was no significant difference 
in the number of GFP expressing cells in each transfection.  These results show that all of the 
plasmids, including pTracer alone, were maintained at similar levels in the populations of 
cultured cells during the entire 30-day time period.  If the Rev protein was acutely toxic, then we 
would expect to see a significant difference in the number of cells expressing GFP.  All of the 
Rev-C transfected cells would have died off quickly resulting in low amounts of GFP expressed, 
while the cells transfected with pTracer alone would have maintained a much higher level of 
GFP expression.  If the basic domain was responsible for the toxicity of Rev, then the cells 
transfected with the un-mutated basic domain plasmids (Sense, Delta Leu-Rich, and LL-FV) 
should have died off quickly resulting in a sharp decline in the amount of GFP expressed and the 
cells transfected with the mutated basic domain plasmids (RR-DL and Delta Basic) should have 
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been less toxic and thus GFP expression would have been maintained longer.  The pTracer alone 
(+ control) transfected cells should have maintained the highest level of GFP expression over 
time because they do not contain any Rev sequences.   
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Figure 14.  FACS Analysis of pTracer/Rev-C Transfected Cells.  Cos-1 cells were transfected, 
using the Lipofectin/OPTI-MEM method, with each of the pTracer/Rev-C expression plasmids 
(described previously and indicated by the key on the right).  Cos-1 alone (no plasmid 
transfected) acted as the mock transfection.  The 8 transfections (5 ug of DNA/Tx) were done in 
100mm plates with a cell density of 2.5 X 106 cells/plate.  Cells were split and re-fed every 3 
days.  On days 3, 6, 12, 18, and 30 days post-transfection FACS was performed on each sample.  
Twenty thousand cells were counted, checking for the expression of GFP.   The data were then 
analyzed using the WinMDI computer program.  
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CHAPTER 5 
RESULTS HYPOTHESIS 2 
 
Construction of Hygromycin Resistant EGFP/RRE Expression Plasmids 
 Previous studies in the lab showed that visna RRE could inhibit Rev activity in 
cotransfections; however, it was not total inhibition.  We hypothesized that we could increase the 
effectiveness of inhibition by adding a protein encoding ORF to the RNA, which has been shown 
to stabilize mRNAs (Ross 1995).  The first thing we did was to construct the new plasmids seen 
in Figure 15.  The plasmid pHygEGFP (Clontech) was digested with Hind III and Sal I to obtain 
a 2.1 kb fragment that contained the ORF encoding a fusion between the hygromycin resistance 
gene and the enhanced green fluorescent protein (EGFP).  This fragment was isolated as 
described and ligated into the vector pCMVlink that had been cut with Hind III and Sal I to 
produce the plasmid pCMVlink-HygEGFP.  The plasmids pCMVlink-RRE-V 7923-8124 (RRE-V), 
pCMVlink-RRE-V 8001-8202 (RNA-V) and pCMVlink-RRE-C #28 were cut with Sal I and Sma I 
to remove the RRE-V, RNA-V or RRE-C fragments.  These fragments were then inserted into 
the newly created plasmid pCMVlink-HygEGFP using the Sal I and Sma I sites.  This produced 
plasmids which encode hygromycin resistance, EGFP and contain RRE decoys on a single 
mRNA.  Each plasmid made was always checked to ensure quality and correct sizing by 
restriction digest analysis and DNA sequencing.    
Development of Hygromycin Resistant/RRE Expressing Cell Lines 
 Cotransfections were done in triplicate with the Hyg-EGFP/RRE-V expression plasmids 
(pCMVlink-HygEGFP) and the Rev-V reporter plasmid, pEnv/L(+) to determine if the 
overexpression of exogenous RRE would decrease Env expression from pEnv/L(+).  As controls, 
we repeated the previous cotransfections that had been shown to decrease Rev and Env 
expression.  None of the cotransfections were able to inhibit Rev or Env expression (data not 
shown) contradicting the previous observations.  Because the cotransfection of plasmids did not 
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produce expected results, we decided to try another approach and make cell lines using the 
hygromycin resistant/RRE expression plasmids (pCMVlink-Hyg EGFP, pCMVlink-Hyg EGFP 
RRE-V, pCMVlink-Hyg EGFP RNA-V, and pCMVlink-Hyg EGFP RRE-C).  Decoy expressing 
cell lines would then be transfected with the pEnv/L(+) and pEnv1772 indicator constructs.  Cos-1 
cells were transfected using the Lipofectin/OPTI-MEM 1 method into eight 60mm plates.  The 
cells were cultured over time using media spiked with 250ug/ml Hygromycin.  Once hygromycin 
resistant cells were obtained and the non-plasmid containing cells were eliminated, the cells from 
each separate transfection were combined into T175 flasks and cultured.  The cell lines were then 
checked by performing FACS to ensure that the cells actually did express the EGFP marker; 
untransfected Cos-1 cells were used as the mock (Figure 16).  The FACS analysis shows that all 
four plasmid-containing cell lines (Hyg EGFP, Hyg EGFP RRE-V, Hyg EGFP RNA-V and Hyg 
EGFP RRE-C) all express EGFP similarly, in terms of both percentage of cells that express and 
in intensity.  These results indicate that each cell line expresses similar quantities of the decoy 
mRNA. 
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Figure 15.  Diagram of Plasmids Used to Make Hygromycin Resistant, EGFP-RRE Expressing 
Cell Lines.  The Hygromycin resistant gene and the EGFP gene are removed from the 
pHygEGFP plasmid using Sal I and Hind III.  The fragment was ligated to the pCMVlink 
plasmid previously cut with Sal I and Hind III.  RRE-V was removed from pCMVlink-RRE-
V7923-8124 using Sal I and Sma I and then inserted into the new pCMVlink-HygEGFP plasmid to 
make the plasmid pCMVlink-HygEGFP-RRE-V.  The RNA-V and RRE-C plasmids were 
constructed the same way. 
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Figure 16.  WinMDI Generated Graph Showing the Expression of EGFP from the RRE 
Expressing Cell Lines.  FACS was performed on each cell line (Cos-1 alone represented by the 
red line, Hyg. alone represented by the black line, RRE-V represented by the blue line and RNA-
V indicated by the green line) using untransfected Cos-1 cells as the baseline to determine EGFP 
expression.    
 
 
Non-Significant Inhibition of Rev-V and Env-V Expression by Exogenous RRE-V in 
Cotransfected Cells 
 Once the inhibitor expressing cell lines were established, we were able to proceed with 
the transfections using the indicator constructs pEnv/L(+) and pEnv/Rev-V1772 (Figure 17) .  Each 
cell line was transfected with pEnv/L(+) and pEnv/Rev-V1772.  Transfected cells were labeled 
with 35S and harvested at the 24 and 48 hour time points.  Immunoprecipations were then done to 
determine the amount of Rev-V and Env-V expression resulting from each transfection and are 
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shown in Figure 18.  As expected, there was no Rev or Env expression in the 2 control lanes, 
Cos-1 cells alone and pCMVlink-HygEGFP (no Rev present) cells alone (lanes 9 and 10).  As 
seen in the previous cotransfection, there was no significant difference in the amount of Rev or 
Env expressed when the indicator constructs were transfected into the different cell lines.  If the 
RRE decoys had functioned as expected, then there should have been less Rev and Env 
expressed in the RRE-V cell lines than in the hygromycin and RNA-V cell lines.   
Phosphorimaging analysis was performed and the results from 3 independent experiments were 
assayed (Figures 19 and 20).  The 2 bar graphs show that there was no significant difference in 
the amount of Rev or Env expressed in any of the cell lines.   
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Figure 17.  Indicator Constructs Used in CoTransfections.  Both plasmids have a CMV IE 
(Cytomegalovirus Immediate Early Promoter) that drives their transcription.  pEnv/L(+) 
expresses both Rev-V and Env-V from Visna Virus strain 1514.  pEnv/Rev-V1772 expresses both 
Rev-V and Env-V from Visna Virus strain 1772. 
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Figure 18.  SDS PAGE Gel of Transfections into RRE Expressing Cell Lines.   The cell lines are 
indicated above each lane.  Lanes 2-4 were cotransfected with 2 ug pEnv/L(+) and lanes 5-7 
were cotransfected with 2 ug pEnv/Rev-V1772.  All samples were 35S labeled and co-
immunoprecipitated for both Rev-V and Env-V.  Lane 1 is the 14C molecular weight standard 
with the sizes (kd) indicated on the left.  Lane 9 is the mock transfection (no DNA added).  Lane 
10 is also a mock (pCMVlink-Hyg EGFP cell line alone, no DNA added).  Hyg represents the 
pCMVlink-Hyg EGFP cell line, RRE-V represents the pCMVlink-Hyg EGFP-RRE-V cell line 
and RNA-V represents the pCMVlink-Hyg EGFP-RNA-V cell line. The locations of Rev-V and 
Env-V are indicated on the right.   
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Figure 19.  Phosphorimager Analysis of Rev-V Expression in Transfected Cell Lines.  The 
columns indicate the average intensity of the Rev-V bands on SDS PAGE gels from each of the 
3 experiments.  The bars indicate the standard deviation of each average.  pEnv represents 
pEnv/L(+), p1772 represents pEnv/Rev-V1772, Hyg represents the pCMVlink-Hyg EGFP cell 
line, RRE-V represents the pCMVlink-Hyg EGFP-RRE-V cell line and RNA-V represents the 
pCMVlink-Hyg EGFP-RNA-V cell line.  
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Figure 20.  Phosphorimager Analysis of Env-V Expression in Transfected Cell Lines.  The 
columns indicate the average intensity of the Rev-V bands on SDS PAGE gels from each of the 
three experiments.  The bars indicate the standard deviation of each average.  pEnv represents 
pEnv/L(+), p1772 represents pEnv/Rev-V1772, Hyg represents the pCMVlink-Hyg EGFP cell 
line, RRE-V represents the pCMVlink-Hyg EGFP-RRE-V cell line and RNA-V represents the 
pCMVlink-Hyg EGFP-RNA-V cell line. 
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CHAPTER 6 
RESULTS HYPOTHESIS 3 
 
Evolution of a RRE-V RNA Aptamer 
 Several studies have shown that SELEX (Systematic Evolution of Ligands by 
Exponential Enrichment) can be used to generate aptamers that can bind to HIV-1 Rev at least 
ten times better than the RRE (Giver et al. 1993a, Giver et al. 1993b, Jensen et al. 1994, Jensen 
et al. 1995).  We, therefore, hypothesized that we could use this same process to evolve aptamers 
that could bind to Rev-V more tightly than the RRE-V.  It is also likely that such aptamers would 
be more efficient Rev decoys.  To see if we could make a better binder RRE-V for Rev-V a 
SELEX oligo had to be made.  This was a 60 nucleotide oligo with a T7 promoter sequence on 
the 5 end, a SP6 promoter sequence on the 3 end and a 30 nt. random sequence in the middle.  
The oligo was PCR amplified using the T7 and SP6 promoters and the resultant DNA was then 
in vitro transcribed, resulting in a pool of RNAs that had known terminal sequences and random 
interior sequences.  This pool of RNAs was used to start the 9 rounds of SELEX.  One round 
consisted of in vitro transcription of DNAs to make RNAs that were then bound to GST Rev-V 
and/or GST cell lysates to select out Rev binders.  The resulting aptamers were then reverse 
transcribed to make cDNAs.  The cDNAs were then PCR amplified and used to start the next 
round of  SELEX. 
 Once 9 rounds of SELEX were completed, RNA binding assays were performed with a 
32P labeled RNA sample from the end of each round.  The binding assays were performed using 
both GST and GST-REV-V proteins.  There should not be any binding of the RNA aptamers to 
the GST protein because it does not contain any Rev sequences.  We expected to see increased 
binding over each round of the SELEX RNA aptamers to the GST-Rev-V protein because each 
round of SELEX should eliminate the non-binding or weaker binding RRE-V aptamers, while 
maintaining and developing stronger binders.  Figure 21A demonstrates that the SELEX 
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generated aptamers did not bind GST.  The data presented in Figure 21B seem to indicate that we 
successfully produced aptamers that specifically bind GST-Rev-V.  However, there does not 
appear to be a clear evolution of a better binding RRE-V ligand through the 9 rounds of SELEX 
as indicated by the fact that the signal intensity does not increase in later rounds (Figure 21B, 
lane 13). 
 It did not appear that there was an evolution of a better binding RRE-V ligand through 9 
rounds of SELEX.  Therefore, we decided to test 1 round of the SELEX ligands to see if it 
could out-compete wildtype RRE-V for binding to Rev-V.  We chose the ligand from round 6 
because it seemed to be the best binder to Rev-V in the binding assay (Figure 21B, lane 7).  We 
synthesized 32P labeled  RNA aptamer from round 6 as well as wildtype RRE-V and then 
competed them against unlabeled wildtype RRE-V and RNA-V for binding to the GST-Rev-V 
protein.  Figure 22A shows the results when labeled wildtype RRE-V is competed against 
increasing 5 fold serial dilutions of unlabeled RRE-V.  The more diluted the unlabeled 
competitor becomes, the more the labeled ligand is bound by the Rev protein.  Figure 22B shows 
the results of labeled RRE-V competed against increasing dilutions of unlabeled RNA-V.  The 
labeled RRE-V would be expected to out-compete the unlabeled RNA-V ligand for binding to 
Rev-V because RNA-V does not specifically bind Rev.  Labeled RRE-V does out-compete 
unlabeled RNA-V for binding to Rev-V in all cases except for in lane 7. The decrease in RRE-V 
binding observed in this lane is probably due a gel loading error.  Figure 23A shows the results 
when the labeled round 6 ligand is competed against increasing dilutions of unlabeled RRE-V.  
In every case involving the unlabeled RRE-V as a competitor,  there is little or no binding of the 
labeled SELEX ligand to Rev-V.  This suggests that the round 6 aptamer does not bind to Rev as 
tightly as does the RRE-V.  Figure 23B shows the results of the labeled round 6 ligand when 
competed against increasing dilutions of unlabeled RNA-V.   The labeled round 6 ligand was 
able to out-compete unlabeled RNA-V for binding to Rev-V.  These results indicate that we were 
 57 
able to produce a functional Rev-V binding aptamer by SELEX, but we were unable to produce a 
better binder for Rev-V than wildtype RRE-V.   
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Figure 21.  12% Urea/Polyacrylamide Gels of Binding Assays of the SELEX RNAs to GST and 
GST-Rev-V.  A.) RNAs labeled with 32P from rounds 2 through 9 of SELEX bound to GST 
protein.  B.) RNAs labeled with 32P from rounds 2 through 9 of SELEX bound to GST-Rev-V 
cell lysate.  Lane 1 is the Phi X174/Hinf1 marker with sizes indicated on the left.  The locations 
of the SELEX aptamer are indicated on the right. Lane 13 contains unbound 32P labeled wildtype 
RRE-V.    
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B.  32P RRE-V + unlabelled RNA-V competitor
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Figure 22.  6% Urea/Polyacrylamide Gels of the 32P Labeled Wildtype RRE-V Competition 
Assays.  A.) Competition Assay with unlabeled wildtype RRE-V.  B.) Competition Assay with 
unlabeled RNA-V.  Lane 1 is the 10 bp molecular weight standard with the 100 bp location 
indicated on the left.  Lanes 2 through 7 contain the competition assays with 1:5 serial dilutions 
of unlabeled wildtype RRE-V/RNA-V.  Lane 8 had no unlabeled RRE-V/RNA-V added to the 
reaction mix.  Lane 10 contains an unbound labeled RRE-V.  The amount of unlabeled RRE-
V/RNA-V competitor is indicated above each lane.  The location of RRE-V is indicated on the 
right.  
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Figure 23.  12% Urea/Polyacrylamide Gels of the 32P Labeled Round 6 SELEX Aptamer 
Competition Assays.  A.) Competition Assay with unlabeled wildtype RRE-V.  B.) Competition 
Assay with unlabeled RNA-V.  Lane 1 is the 10 bp molecular weight standard with the 100 bp 
location indicated on the left.  Lanes 2 through 7 contains the competition assays with 1:5 
dilutions of unlabeled wildtype RRE-V/RNA-V.  Lane 8 had no unlabeled RRE-V/RNA-V 
added to the reaction mix.  Lane 10 contains an unbound labeled Round 6 ligand.  The amount of 
unlabeled RRE-V/RNA-V competitor is indicated above each lane.  The location of the Round 6 
RRE-V ligand is indicated on the right. 
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CHAPTER 7 
RESULTS HYPOTHESIS 4 
 
Rev-C Trans-activation of RRE-V 
 Previous studies indicated that lentiviral Rev proteins can cross-activate.  In particular, 
our lab has shown in preliminary experiments that CAEV Rev can trans-activate thru the Visna 
Virus RRE, albeit at a reduced efficiency (Hansen 2001).  To quantify the degree to which Rev-
C can trans-activate through the RRE-V, we performed multiple cotransfections with the 
reporter plasmid pEnv/L(-) and the effector constructs pCMVlink, pCMVRev-V and pCMVRev-
C seen in Figure 24.  The transfections were repeated 4 times using the Trans-IT LT1method 
with a 1:4 ratio of effector plasmid to reporter plasmid.  The cells were labeled with 35S and 
harvested at 48 hours post-transfection.  The cell lysates were then immunoprecipitated for Env 
(Env-V), Rev-V and Rev-C. The results of a representative experiment are seen in Figure 25.  No 
Env is observed in Figure 25A lanes 2 and 3 which contain the mock (pTracer + pCMVlink) and 
the negative control (pEnv/L(-) + pCMVlink).  Neither of those transfections contain Rev 
sequences and, therefore, should not express Env.  As expected, lane 4 reveals a strong Env band 
as a result of the transfection of  pEnv/L(-) + pCMVRev-V and in lane 5 (Figure 25A) there is a 
very faint Env band as the result of the transfection pEnv/L(-) +  pCMVRev-C.   
 Figure 25B shows the results of the Rev immunoprecipitations.  The two mock 
transfections (pTracer + pCMVlink and pEnv/L(-) + pCMVlink) did not produce either a Rev-V 
(lanes 3 and 5) or a Rev-C (lanes 4 and 6) band as expected.  Lane 7 contains a Rev-V band as 
expected when pEnv/L(-) was transfected with pCMVRev-V and lane 8 contains a Rev-C band 
as expected when pEnv/L(-) was transfected with pCMVRev-C.  The Rev-C band was less 
intense than the Rev-V band indicating that Rev-C was less well expressed.  The gels were 
quanititated using phosporimager analysis to determine the amounts of Rev and Env expressed 
and the results can be seen in Figure 26.  The amount of Env-V was normalized to the amount of 
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Rev present in each lane.  Rev values were first adjusted according to the number of methionines 
found in Rev-V (8) and Rev-C (5).  The normalized Env expression trans-activated by either 
Rev-V or Rev-C in 3 independent experiments is shown in Figure 26.  In all 3 cases, Rev-C 
trans-activated thru the RRE-V less well than did Rev-V.  
 
ENV/L(-)P
CMV IE Poly A
Env-V1514
Rev-V1514
STOP
CMVlinkP
CMV IE Poly A
CMVRev-CP
CMV IE Poly A
Rev-C
CMVRev-VP
CMV IE Poly A
Rev-V
 
 
Figure 24.  Plasmids Used in Rev-C Cross-activation Study.  The 3 effector constructs used are:  
pCMVlink, pCMVRev-V and pCMVRev-C and pEnv/L(-) is the indicator construct.  All four 
plasmids have a CMV IE (Cytomegalovirus Immediate Early Promoter) that drives their 
transcription.  pCMVlink is a high-level expression plasmid (it does not contain any Rev or Env 
sequences).  pCMVRev-V expresses the Visna Virus Rev protein.  pCMVRev-C expresses 
CAEV Rev protein.  pEnv/L(-) expresses both Rev-V and Env-V from Visna Virus strain 1514.  
It has a termination codon located in the second Rev ORF which produces a truncated, non-
functional Rev protein and only expresses Env protein if Rev is provided in trans. 
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Figure 25.  SDS PAGE Gels of Env and Rev Immunoprecipitations.  Cos-1 cells were 
transfected (1:4 ratio) with a reporter construct (pEnv/L(-)) and an effector construct.  The DNA 
cotransfection mixes are indicated above each lane.  The cells were then 35S labeled and 
immunoprecipitated for Env and either Rev-V or Rev-C.  A.) 10% SDS PAGE from Env 
immunoprecipitations.  B.) 15% SDS PAGE from Rev-V and Rev-C immunoprecipitations.  
Lane 1 is the 14C molecular weight standard with the sizes (kDal) indicated on the left.  The 
pTracer + pCMVlink transfection is the mock transfection and the pEnv/L(-) + pCMVlink is the 
negative control.  Link represents pCMVlink, Rev-V represents pCMVRev-V and Rev-C 
represents pCMVRev-C.  The Env sample was immunoprecipitated with either anti-Env and the 
Rev samples were immunoprecipitated with anti-Rev-V and anti-Rev-C (indicated above each 
lane).  The locations of Env, Rev-V and Rev-C are indicated on the right.   
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Figure 26.  Phosporimager Analysis of Env Expression.  The columns indicate the percent of 
Env expression from the cotransfections.  The percent of Env expression was calculated by 
normalizing the Rev values according to the number of methionines in each.  Each Env value 
was then normalized to the amount of Rev present.  Rev-V directed Env expression was set at 
100% and the Rev-C driven expression was calculated by dividing the normalized Env-C value 
by the Env-V value and multiplying by 100.  The blue columns represent Rev-V trans-activation 
and the red columns represent Rev-C trans-activation.     
 
 After showing that Rev-C could trans-activate RRE-V but at a lower efficiency than Rev-
V, we decided to see if the reason it did not trans-activate the RRE-V as well was because Rev-C 
does not bind RRE-V as well as Rev-V can.  To study this question, we did RNA binding assays 
using Rev-C proteins and various RREs that were labeled with 32P.  After making the Rev-C 
proteins using in vitro translations, we electrophoresed them on a SDS PAGE gel to ensure they 
were the correct size and expressing Rev-C (+ only) (data not shown).  We then in vitro 
transcribed RRE-V, RRE-C (+), RRE-C (-) and RNA-V RNA in the presence of  32P rUTP.  
Those probes were checked for quality as well by running them out on a 6% urea/polyacrylamide 
gel (data not shown).  The binding assays were performed as described previously and the results 
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are shown in Figure 27.  Lane 2 containing Rev-C(+) + RRE-C (+) gives the expected results 
with a high intensity band indicating the presence of RRE-C.  Lane 3 containing Rev-C (+) + 
RRE-V shows a very light band indicating the presence of RRE-V.  Lanes 4 and 5 contain the 
negative control binding assays (Rev-C(+) + RRE-C(-) and Rev-C(+) + RNA-V) and do not 
show any Rev bands.  These results were phosphorimager analyzed and resulted in a bar graph 
depicting the difference in (percentage) binding that Rev-C had to  RRE-C and RRE-V.  Figure 
28 indicates that Rev-C binds RRE-V less than 7% as well as it binds to  RRE-C.   
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Figure 27.  Representative 6% Urea/Polyacrylamide Gel of RNA Binding Assays.   35S labeled 
Rev-C (+ and -) IVT proteins were bound to a 32P labeled RRE (either RRE-C(+), RRE-C(-), 
RRE-V or RNA-V).  RRE-C transfections were immunoprecipitated with anti Rev-C and the 
RRE-V/RNA-V transfections were immunoprecipitated with anti Rev-V.  Lane 1 is the 32P 
labeled 100 bp molecular weight standard with the sizes indicated on the left.  The locations of 
Rev-V and Rev-C are indicated on the right.   
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Figure 28.  Phosporimager Analysis of Rev-C Binding to RRE-V and RRE-C.  The columns 
indicate the percent of Rev-C binding to RRE-V and RRE-C from the RNA binding assays.  The 
percent of Rev-C binding was calculated by dividing the RRE-C values by the RRE-V values 
and multiplying by 100. RRE-C binding by Rev-C was set at 100% and RRE-V binding by Rev-
C was calculatd as stated earlier.  The red columns represent RRE-C and the blue columns 
represent RRE-V.     
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CHAPTER 8 
DISCUSSION 
 
Hypothesis 1 
FACS Analysis of Cells Expressing Rev-C 
 Based on the graphical analysis (Figure 14) of Cos-1 cells transfected with Rev-C 
expression plasmids, it can be concluded that Rev-C is not acutely toxic to cells.  There was not a 
significant difference in the how quickly the Rev/GFP transfected cells died.  Over the 30-day 
time period, none of the transfected cells were able to maintain a higher level of GFP expression 
over the other transfected cells.  If Rev had been acutely toxic to cells, we would have expected 
the number of Rev-C/GFP transfected cells to decrease more rapidly compared to the pTracer 
alone transfected cells.  From these results, we were able to conclude that Rev may be toxic to 
cells, it just is not acutely toxic.  The previous experiment that indicated the basic domain of Rev 
might be toxic was done over a longer period of time than our experiment was done.  Those cells 
were transfected and G418 selected for a long period of time.  We did not use antibiotic selection 
on our transfected cells.  However, we did lose some transfected cells each time we split and re-
fed them, but the loss of transfected cells should have been relatively equal for the different 
DNAs.  Thus, Rev may be toxic to cells over time, but it is not acutely toxic and therefore it 
would not be a good way to control lentiviral replication by overexpressing the basic domain of 
Rev.     
 
Hypothesis 2 
Development of Hygromycin Resistant/RRE Expressing Cell Lines 
 The results from cotransfections done with the new RRE-V expression plasmids 
(pCMVlink-HygEGFP) and the Rev-V reporter plasmid (pEnv/l(+)) (data not shown) and also 
the repeat cotransfections earlier were surprising in that none of them seemed to inhibit Rev or 
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Env expression.  Those results contradicted previous experimental results that had indicated 
RRE-V would inhibit Rev and Env expression by acting as a decoy for Rev binding.  As a result 
we decided upon an alternate approach; to develop hygromycin resistant/EGFP and RRE 
expressing cell lines.  Before each transfection into Cos-1 cells, the plasmids were checked for 
identity.  Once the cell lines were established, we performed FACS analysis to ensure that the 
cell lines were expressing GFP.  As can be seen in Figure 16, all 3 cell lines were expressing 
GFP and are doing so at similar levels validating the results of the immunoprecipitations seen in 
Figures 17, 18, and 19.  Because they were expressing GFP at approximately the same amount, 
Rev and Env protein expression after transfections with pEnv/L(+) and pEnv1772 are considered 
equal and the results from the different cell lines can be compared as such.   
 The data from the cell line transfection experiments (Figures 18, 19, and 20) indicate that 
the new hygromycin resistant/EGFP-RRE expression constructs do not inhibit Env expression 
and hence, Rev activity.  We had hypothesized that the new hygromycin resistant constructs 
would actually be better inhibitors of Rev than the link + RRE-V constructs.  They were 
designed to produce a more stable decoy mRNA.  There was no significant inhibition of Rev or 
Env in any of the transfections (Figure 18, lanes 2-7).  Because the 2 control lanes (Figure 18, 
lanes 9 and 10) gave the expected results of no Rev or Env expression we know that the Cos-1 
cells were not contaminated and the pCMVlink-Hyg-EGFP cell lines are also not contamintated 
with Rev or Env.   We had hypothesized that the RRE cell lines would express less Rev and Env 
than the hygromycin or the RNA cell lines because the expressed RREs would act as decoys and 
bind Rev.  However, this was not the case.  The phosporimager analysis of both Rev and Env 
expression in Figures 19 and 20 further confirm the that there was no significant inhibition of 
Rev or Env expression when RRE-V expressing cell lines were transfected with plasmids 
expressing both Rev and Env. The new hygromycin/RRE constructs may not have worked for 
several reasons.  First, exogenous RREs may not be able to act as decoys and bind Rev as 
previously thought, but that is unlikely to be correct based on published data in other lentiviral 
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systems.  We believe the hygromycin insert may be binding to and forming a secondary structure 
with the RRE, which is preventing its binding to Rev.  Another plausible explanation is that the 
decoy RNAs may be translating so well that the ribosomes are occluding the RRE, thus 
preventing it from binding Rev.   
 
Hypothesis 3 
Evolution of a RRE-V RNA Aptamer 
 Based on published data we hypothesized that we could produce aptamers that could bind 
Rev-V more tightly than RRE-V using SELEX.  We first made an oligo we believed would give 
us the best chance at producing a tight binding RRE-V.  We then used the resulting aptamers 
from SELEX to perform RNA binding assays (Figures 20 A & B) with GST and GST-Rev-V 
which produced both promising and distressing results.  It is apparent from Figure 20A that we 
were successful in producing a selective binder because none of the aptamers bound to GST.  At 
first glance the results seen in Figure 20B were also very promising.  It indicated that we were 
able to produce a RRE aptamer that would bind GST-Rev-V.  However, we expected to see an 
increase in the binding of Rev by the aptamers as more rounds of SELEX were completed.  That 
would have indicated that we were able to amplify a very tight binding aptamer.  However, it 
appears that we were unable to selectively amplify 1 or several tight binders over time. 
 In order to determine whether our SELEX aptamer would out-compete wildtype RRE-V 
for binding to Rev-V, we performed competition assays.  Figure 21A gave us the expected 
results showing the labeled RRE-V was able to out-compete the unlabeled RRE-V competitor as 
it is diluted.  Figure 21B is the positive control for this experiment.  The unlabeled competitor is 
RNA-V, which is the non-binding RRE.  It does not bind Rev-V and thus in all cases the 
labeled RRE-V should out-compete it.  Other than lane 7, it gave the expected results.  The 
absence of a band in lane 7 is probably due to a loading error.  If our aptamer was a better binder 
to Rev-V than wildtype RRE-V then, the results in Figure 22A would have been much different.  
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We had predicted that our aptamer would out-compete the unlabeled RRE-V, but in all cases the 
unlabeled wildtype competitor was the better binder.  The absence of a band in lane 8 is difficult 
to explain, however.  There was no competitor added to that reaction, so there should have been 
a band present.  Figure 22B again backs up our statement that we were able to make a RNA 
ligand that binds Rev-V.  In all of the reactions using RNA-V as the unlabeled competitor, our 
aptamer was able to out-compete it for binding to Rev-V.  Thus, while we were able to produce a 
functional RRE-V aptamer from SELEX we were not able to produce a better binding RRE-V 
that could be used as a decoy.   
There are several possible reasons why we were unable to produce a better binding RRE.  
First, we may not have done enough rounds of SELEX.  Perhaps if we had continued with more 
rounds, then we might have been able to evolve a better binder.  However, we do not believe that 
would happen.  It is very possible that the better binder we are seeking is not in our library.  
Perhaps if we just re-initiate transcription at the beginning and start with a new library we may 
include a better binder or if we make a different oligo with a larger unknown sequence it would 
enable us to broaden our library and encompass a better binder. 
 
Hypothesis 4 
Rev-C trans-activation of RRE-V 
Numerous reports have shown that lentiviruses can trans-activate across species. 
Experiments in our lab have suggested that Rev-V can trans-activate thru the RRE-C but at 
lower levels than it does RRE-V.  This led us to hypothesize that Rev-C can cross-activate RRE-
V but at a lower efficiency than it can RRE-C.  We initially did cotransfections assays to 
determine if Rev-C can in fact trans-activate RRE-V.  Based on the results seen in Figures 25A 
and B, we were able to conclude that Rev-C can trans-activate thru the RRE-V.  As expected in 
Figure 25A, the two control transfections did not produce an Env-V band validating our 
experimental data from this gel.  It is evident from this gel that Rev-C does not trans-activate 
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through the RRE-V as well as Rev-V based on the intensities of the Env bands in lanes 4 and 5.  
In the Rev gel (Figure 25B), the Rev-C band is also not as dark as the Rev-V band which is 
comparable to the results seen in Figure 25A.  Quantitations done from the results of these 2 gels 
(Figure 26) show that on average Rev-C trans-activates through the RRE-V at 19.7% the amount 
observed with Rev-V.  Our hypothesis that Rev-C does not trans-activate RRE-V as well as Rev-
V because it does not bind as well, was supported by the results seen in Figures 27 and 28.  The 
RNA binding assays confirm that Rev-C does not bind RRE-V as well as it can bind RRE-C 
(Figure 27, lanes 2 and 3).  In fact it binds RRE-V at only 5.2% the efficiency that it binds its 
own RRE (Figure 28).  Based on all of these results, we can state that Rev-C can trans-activate 
RRE-V but at a lower capacity than RRE-C because Rev-C binds the RRE-V less efficiently than 
does the wildtype Rev protein.    
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APPENDIX 
 
Table 2.  List of Abbreviations Used 
 
AIDS -Acquired Immune Deficiency Syndrome 
APS -ammonium persulfate 
bp -base pairs 
CA -major capsid protein 
CAEV -Caprine Arthritis Encephalitis Virus 
cpm -counts per minute 
CMV IE  -Cytomegalovirus immediate early promoter 
CO2 -carbon dioxide 
CSA -casamino acids 
C-terminal -carboxy terminal 
dATP -deoxyadenosine triphosphate 
ddH20 -double distilled water 
DEPC -diethylpyrocarbonate 
DMEM -Dulbeccos Minimal Essential Medium 
DMSO -dimethyl sulfoxide 
DNA -deoxyribonucleic acid 
DS-DNA -double stranded deoxyribonucleic acid 
DTT -DL-dithiothreitol 
dTTP -deoxythymidine triphosphate 
dUTP -deoxyuridine triphosphate 
E. coli -Escherichia coli bacteria 
EDTA -ethylenediaminetetraacetic acid 
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Table 2 (continued) 
EGFP -enhanced green fluorescent protein 
EIAV -Equine Infectious Anemia Virus 
eIF-5A eukaryotic initiation factor 5A 
Env-V -Visna Virus envelope protein 
EtOH -ethanol 
FACS -Fluorescence Activated Cell Sorter 
FCS -fetal calf serum 
FIV -Feline Immunodeficiency Virus 
Gag -group specific antigen 
GFP -green fluorescent protein 
gp -glycoprotein 
GST -glutathione-S-transferase 
H202 -hydrogen peroxide 
HIV-1 -Human Immunodeficiency Virus type 1 
HTLV -Human T cell Leukemia Virus 
Hyg -hygromycin 
IP -immunoprecipitation 
IPTG -isopropyl-ß-D-thiogalactopyranoside 
kDal -kilodaltons 
M -Molar 
MA -matrix protein 
MEM -Earles Minimal Essential Medium 
mg -milligram 
MgCl2 -magnesium chloride 
ml -milliliter 
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Table 2 (continued) 
mM -millimolar 
MnCl2 -manganese chloride 
MOPS -3-(N-morproline) propane sulfonic acid 
mRNA -messenger ribonucleic acid 
NaCl -sodium chloride 
NaOAc -sodium acetate 
NaOH -sodium hydroxide 
NC -nucleocapsid protein 
NES -nuclear export signal 
NLS -nuclear localization signal 
NPC -nuclear pore complex 
OD -optical density 
oligo -oligonucleotide 
ORF -open reading frame 
PAGE -polyacrylamide gel electrophoresis  
PBS -phosphate buffered saline 
PCR -polymerase chain reaction 
PEG -polyethylene glycol 
Rev-C -Caprine Arthritis Encephalitis Virus Rev protein 
Rev-V -Visna Virus Rev Protein 
RNA -ribonucleic acid 
RRE-C -Caprine Arthritis Encephalitis Virus Rev Response Element 
RRE-V -Visna Virus Rev Response Element 
RT -reverse transcriptase 
RT° -room temperature 
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Table 2 (continued) 
SDS -sodium dodecyl sulfate 
SELEX -Systematic Evolution of Ligands by Exponential Enrichment 
SIV -Simian Immunodeficiency Virus 
SV40 -Simian Virus 40 
TAE -Tris-acetate-EDTA buffer 
TBE -Tris-borate-EDTA buffer 
TBS -Tris buffered saline 
TCA -trichloroacetic acid  
TE -Tris-EDTA buffer 
tRNA -transfer ribonucleic acid 
uCi  -microcurie 
ug  -microgram 
ul -microliter 
UV  -ultraviolet 
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